Advance universal influenza vaccine - flu mosaic version 2 (FLUMOSV2)
Active Awarded Last action
- Contract number
- 75N91021F00004
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $102,761,983
Award facts
- Contract value 72% obligated
-
- $141,656,003.00 Current, with exercised options
- $142,262,456.00 Potential, with all options
- Completion date 57% complete
- Current and potential, with all options
- Funding agency
- National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Exercise an Option | $102,761,983 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $2,296,026 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $12,804,695 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $3,392,323 | |
| Exercise an Option | $1,639,241 | |
| Original award | $18,761,735 |
Show all 11
About this award
Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc., was awarded a delivery order on February 16, 2021, valued at $142.3 million for the Advance Universal Influenza Vaccine—Flu Mosaic Version 2 (FluMosV2) project. This cost-plus-fixed-fee delivery order, funded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the National Institutes of Health, will be performed in Frederick, Maryland, with an ultimate completion date of January 28, 2031. The contract does not utilize a set-aside designation, indicating Leidos Biomedical Research won this award through competitive capabilities. As a Federally Funded Research and Development Center (FFRDC) contractor, Leidos Biomedical Research provides biomedical research and facilities support services, and this contract aligns with the company's demonstrated expertise in vaccine development and infectious disease research for federal agencies.
The FluMosV2 project represents a significant federal commitment to developing an advanced universal influenza vaccine under NIAID's broad mission to conduct and support research on infectious diseases. Leidos Biomedical Research's extensive track record includes conducting research on influenza and other infectious diseases, performing clinical trials, and supporting vaccine development initiatives for NIH-affiliated agencies. The 10-year performance period reflects the complexity and multi-phase nature of vaccine development, from research and development through clinical validation. This award underscores NIAID's continued investment in pandemic preparedness and the prevention of seasonal influenza through innovative vaccine platforms designed to provide broader protection across multiple influenza strains.
Quick answers
Who was awarded contract 75N91021F00004?
75N91021F00004 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on February 16, 2021.
How much is contract 75N91021F00004 worth?
The government has obligated $102,761,983 on 75N91021F00004. Its current value, with exercised options, is $141,656,003. Its potential value, with all options, is $142,262,456.
Which agency awarded contract 75N91021F00004?
National Cancer Institute (National Institutes of Health) awarded 75N91021F00004, with funding from National Institute of Allergy and Infectious Diseases (National Institutes of Health).
Is contract 75N91021F00004 an order under another contract?
Yes. 75N91021F00004 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91021F00004 competed?
The extent of competition for 75N91021F00004 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award